ImmunityBio (IBRX) traded lower in a modest pullback as the market continues to digest the fallout from the FDA’s March 13, 2026 warning letter addressing allegedly false or misleading promotional statements tied to Anktiva. With no clear new company catalyst surfacing in the latest filings and releases, the tape action looks consistent with lingering risk repricing after a high-visibility regulatory event and the associated legal noise that followed in March and early April.

The FDA warning letter cited a TV advertisement and a podcast, stating the communications misbranded Anktiva and suggested uses beyond the drug’s approved labeling, and also noted a failure to submit the podcast at the time of initial dissemination as required. That kind of compliance headline can pressure biotech multiples because it raises questions about promotional controls, potential enforcement escalation if remediation is deemed insufficient, and management distraction at a time when the company is trying to broaden adoption and pursue additional indications.

In an April 6, 2026 Form 8‑K, ImmunityBio said it submitted a comprehensive response to the FDA’s Office of Prescription Drug Promotion and outlined corrective actions. The filing said the company removed the identified podcast from its corporate website, requested removal from third-party platforms, and stated the TV advertisement cited was never broadcast or disseminated; it also described enhanced compliance steps such as expanded promotional review protocols, executive training, and external regulatory oversight. Even with remediation underway, stocks often continue to sag in the weeks after a warning letter as investors reassess probability-weighted outcomes and as class-action deadlines and headlines keep the issue in view.

Key swing factors are whether the FDA signals that the company’s corrective communications are adequate, whether additional promotional materials come under scrutiny, and whether legal proceedings widen or narrow in scope as plaintiff-deadline milestones approach. Investors will also be watching for fresh commercial updates on Anktiva net product revenue and unit growth to determine whether demand momentum can offset the compliance narrative.